The enrichment of Arg1+ILC2s and ILCregs facilitates the progression of endometriosis: A preliminary study

Zhimin Lu, Hao Wang, Zhangyun Gong, Peipei Guo, Caihua Li, Kaihuan Bi, Xuqing Li, Chen Ya, Ya Chen, Anan Pan, Yuping Xu, Ping Zhou, Zhaolian Wei, Huanhuan Jiang, Yunxia Cao
International immunopharmacology · 2023 · vol. 121 , pp. 110421 · doi:10.1016/j.intimp.2023.110421 · PMID:37302364 · W4380194069
article OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study investigated the role of Arg1+ILC2s and ILCregs in endometriosis progression, finding their enrichment contributes to disease advancement.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Lymphocytes Lymphocytes Lymphocytes Lymphocytes Lymphocytes Lymphocytes Lymphocytes Lymphocytes Lymphocytes Lymphocytes

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (43)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-29T00:33:36.739615+00:00
License: CC0 · commercial use OK